Signs your dose needs adjustment Increase dose consideration: Minimal response after 3-4 weeks at current dose, stable weight and measurements despite consistent protocol adherence, absence of any subjective improvements in energy or fasted tolerance
The penetration rationale is borrowed, not AHK-Cu-specific
doi: 10.1038/s41467-017-02444-w 79 Jens RoseFAnne-MarieJTamTTNNKasperDRLine RrbkO
Studies have demonstrated that the inhibition of the MAPK/ERK pathway can promote oligodendrocyte generation and recovery in demyelinating diseases, suggesting a potential therapeutic approach for DN (Suo et al., 2019)
*Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids*
Targeting BTK with FDA-approved anticancer drugs, such as acalabrutinib and ibrutinib, which are metabolized by the CYP3A enzyme, common to both fungi and humans, can be combined with fungal morphogenesis inhibitors to enhance the apoptotic effect [183]